{"database": "lobbying", "table": "lobbying_activities", "rows": [[1735372, "b097d107-4b34-4f8a-aaba-2151ff98c723", "Q3", "THE INGRAM GROUP LLC", 400577737, "ELI LILLY AND COMPANY", 2015, "third_quarter", "PHA", "S.2030, Advancing Targeted Therapies for Rare Diseases Act of 2015.\nH.R.6, 21st Century Cures Act.\nGeneral issues related to the biopharmaceutical and pharmaceutical industries.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2015-10-16T17:45:49.073000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1735372"], "units": {}, "query_ms": 107.19541809521616, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}